5 Reasons to Buy Vertex Pharmaceuticals Now
Vertex Pharmaceuticals (NASDAQ: VRTX) defied 2022's bear market thanks to its tangible business progress. Over the course of the year, the biotech company and its partner Crispr Therapeutics brought their treatment candidate for blood disorders toward the commercialization finish line. They completed regulatory requests in the U.K. and Europe. And they're set to complete the request for U.S. Food and Drug Administration approval in the first quarter.
Vertex has started off this year with gains too, and its winning streak may be far from over. In fact, there are five reasons to buy Vertex right now -- and hold on for the long term. Let's take a closer look at why this biotech stock is likely to deliver earnings and share price performance well into the future.
So, what are the five reasons to buy Vertex? Five potential product launches over the coming five years. It's as simple as that. Vertex's strong late-stage pipeline has what it takes to deliver a whole new era of growth. And this growth won't depend on one single treatment area. This is significant because, in the past, some investors worried about Vertex's dependence on its core cystic fibrosis portfolio.
Source Fool.com
